Trending...
- "The Mystery of Emma Thorn" Earns Nomination & Official Selection of the New Media Film Festival
- California: Governor Newsom highlights mental health resources for veterans as Middle East conflict continues
- New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 10, 2022, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 28,250 shares of common stock and 14,100 restricted stock units ("RSUs") to eight new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $24.93 per share, Mirum's closing trading price on August 10, 2022, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum's approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Please view the warnings and precautions available in the Prescribing information or, for more information, visit LIVMARLI.com.
More on The Californer
Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum's second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
More on The Californer
Learn more about Mirum by visiting www.mirumpharma.com. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
Contacts
Investor Contacts:
Ian Clements, Ph.D.
ir@mirumpharma.com
Sam Martin
Argot Partners
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Each stock option has an exercise price per share equal to $24.93 per share, Mirum's closing trading price on August 10, 2022, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum's approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Please view the warnings and precautions available in the Prescribing information or, for more information, visit LIVMARLI.com.
More on The Californer
- California: Governor Gavin Newsom announces appointments 3.17.2026
- Owl Publishers Expands Support for Authors with Complete Book Publishing Services
- Jet Set: The Ultimate Coachella Afterparty
- Robyn Chu Launches Sensory Wellness: The Art and Science of Thriving
- JiT Home Buyers Highlights Challenges of Selling Homes That Require Major Repairs
Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum's second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
More on The Californer
- Heritage at Manalapan Introduces New Single-Family Home Community in One of Monmouth County's Most Desirable Locations
- Compliant Workspace announces partnership with Blackpoint Cyber
- City of Long Beach Issues a Heat Alert and Advises Residents to Take Precautions Against Heat
- Brass-SEO Drops Price to $35/Month While Adding New Features for Small Business SEO
- Michigan Homeowners Urged to Act on Rising Basement Waterproofing Needs Amid Severe Flood
Learn more about Mirum by visiting www.mirumpharma.com. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
Contacts
Investor Contacts:
Ian Clements, Ph.D.
ir@mirumpharma.com
Sam Martin
Argot Partners
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Filed Under: Business
0 Comments
Latest on The Californer
- Impact Filtration Appoints Alejandro Sturniolo as Head of Sustainability to Engineer High-Performance, Water-Positive Infrastructure
- Machine Vision Products adds Team A.T.E to its North American sales channel
- Recording Academy Member Joanna Pearl Honors Kim Cousins at 77th Annual Lake Elsinore Gala
- Twitch Streamer Caiuwus Emerges From "Streamer University" Spotlight With New Ambitions for 2026
- The Best Cartier Bracelet Dupes to Buy Right Now
- Xycota Biosciences Announces Nature Portfolio Publication Supporting Brain Repair Platform Targeting FTD and ALS
- Long Beach Parks, Recreation and Marine to Update Operating Hours and Programming at City Gyms
- Fabian Starr Announces "Back to the Arcade" Remix Album
- Attn: Book Critics, Poetry Lovers & Rock Stars: Help Rescue All these Great Poems from Obscurity
- Brainfyre Public Relations Introduces Program to Help Founders Build Media Readiness
- 106 Years Strong: The Liberty Group Celebrates a Century-Plus of Service and Unveils a Unified Family of Companies
- What they are saying: Overwhelming support for Governor Newsom's historic expansion of California's behavioral health capacity and treatment
- Airport Transportation Reaches All Five Continents Through Global Transportation Partner Network
- THINKWARE Announces Limited-Time St. Patrick's Day Discounts on ARC Series and F70 PRO Dash Cams
- ShutterChefs Launches AI Food Photography Platform — Pro Menu Images Under $1 Per Photo
- Here's how California Paralympians represented Team USA at Milano Cortina 2026
- Lowest Van Rental Prices of the Year Announced with Code LAX2026
- Acquisition of Israeli Defense Manufacturing Platform to Accelerate AI-Driven Autonomous Systems: VisionWave Holdings, Inc.: (N A S D A Q: VWAV)
- M.S. Sensual Scents Brings Aromatherapy and Natural Wellness to Victorville
- HRC Fertility to Celebrate Grand Opening of New Beverly Hills Location During National Infertility Awareness Week